Cargando…

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review

BACKGROUND AND AIMS: Management of Crohn’s disease and ulcerative colitis has typically relied upon treatment intensification driven by symptoms alone. However, a ‘treat-to-target’ management approach may help to address underlying inflammation, minimise disease activity at early stages of inflammat...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombel, Jean-Frédéric, D’haens, Geert, Lee, Wan-Ju, Petersson, Joel, Panaccione, Remo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008150/
https://www.ncbi.nlm.nih.gov/pubmed/31403666
http://dx.doi.org/10.1093/ecco-jcc/jjz131
_version_ 1783495425859256320
author Colombel, Jean-Frédéric
D’haens, Geert
Lee, Wan-Ju
Petersson, Joel
Panaccione, Remo
author_facet Colombel, Jean-Frédéric
D’haens, Geert
Lee, Wan-Ju
Petersson, Joel
Panaccione, Remo
author_sort Colombel, Jean-Frédéric
collection PubMed
description BACKGROUND AND AIMS: Management of Crohn’s disease and ulcerative colitis has typically relied upon treatment intensification driven by symptoms alone. However, a ‘treat-to-target’ management approach may help to address underlying inflammation, minimise disease activity at early stages of inflammatory bowel disease, limit progression, and improve long-term outcomes. METHODS: A systematic literature review was conducted to identify data relevant to a treat-to-target approach in inflammatory bowel disease, published between January 1, 2007 and May 15, 2017. RESULTS: Consistent with recommendations of the Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE] working group, studies have investigated factors influencing the achievement of both endoscopic and histological mucosal healing and patient-level outcomes in inflammatory bowel disease [IBD]. Histological healing and biomarker levels have also been shown to be modifiable outcomes. Although there is a lack of prospectively derived evidence validating mucosal healing as a treatment target, data are emerging to suggest that targeting mucosal healing or inflammation rather than symptoms may be cost-effective in some settings. The review highlighted several strategies that may support the implementation of a treat-to-target approach in IBD. The prospective randomised CALM study demonstrated how tight control [whereby treatment decisions are based on close monitoring of inflammatory biomarkers] leads to improvements in endoscopic and clinical outcomes. The review also considered the influence of coordinated care from a multidisciplinary team and patient engagement with improved adherence, as well as the role of therapeutic drug monitoring in inflammatory bowel disease management. CONCLUSIONS: A treat-to-target strategy may impact on disease progression and improve outcomes in inflammatory bowel disease. Prospective studies including long-term data are required to ensure that the most appropriate targets and strategies are identified.
format Online
Article
Text
id pubmed-7008150
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-70081502020-02-13 Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review Colombel, Jean-Frédéric D’haens, Geert Lee, Wan-Ju Petersson, Joel Panaccione, Remo J Crohns Colitis Review Article BACKGROUND AND AIMS: Management of Crohn’s disease and ulcerative colitis has typically relied upon treatment intensification driven by symptoms alone. However, a ‘treat-to-target’ management approach may help to address underlying inflammation, minimise disease activity at early stages of inflammatory bowel disease, limit progression, and improve long-term outcomes. METHODS: A systematic literature review was conducted to identify data relevant to a treat-to-target approach in inflammatory bowel disease, published between January 1, 2007 and May 15, 2017. RESULTS: Consistent with recommendations of the Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE] working group, studies have investigated factors influencing the achievement of both endoscopic and histological mucosal healing and patient-level outcomes in inflammatory bowel disease [IBD]. Histological healing and biomarker levels have also been shown to be modifiable outcomes. Although there is a lack of prospectively derived evidence validating mucosal healing as a treatment target, data are emerging to suggest that targeting mucosal healing or inflammation rather than symptoms may be cost-effective in some settings. The review highlighted several strategies that may support the implementation of a treat-to-target approach in IBD. The prospective randomised CALM study demonstrated how tight control [whereby treatment decisions are based on close monitoring of inflammatory biomarkers] leads to improvements in endoscopic and clinical outcomes. The review also considered the influence of coordinated care from a multidisciplinary team and patient engagement with improved adherence, as well as the role of therapeutic drug monitoring in inflammatory bowel disease management. CONCLUSIONS: A treat-to-target strategy may impact on disease progression and improve outcomes in inflammatory bowel disease. Prospective studies including long-term data are required to ensure that the most appropriate targets and strategies are identified. Oxford University Press 2020-02 2019-08-12 /pmc/articles/PMC7008150/ /pubmed/31403666 http://dx.doi.org/10.1093/ecco-jcc/jjz131 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Colombel, Jean-Frédéric
D’haens, Geert
Lee, Wan-Ju
Petersson, Joel
Panaccione, Remo
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
title Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
title_full Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
title_fullStr Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
title_full_unstemmed Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
title_short Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
title_sort outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008150/
https://www.ncbi.nlm.nih.gov/pubmed/31403666
http://dx.doi.org/10.1093/ecco-jcc/jjz131
work_keys_str_mv AT colombeljeanfrederic outcomesandstrategiestosupportatreattotargetapproachininflammatoryboweldiseaseasystematicreview
AT dhaensgeert outcomesandstrategiestosupportatreattotargetapproachininflammatoryboweldiseaseasystematicreview
AT leewanju outcomesandstrategiestosupportatreattotargetapproachininflammatoryboweldiseaseasystematicreview
AT peterssonjoel outcomesandstrategiestosupportatreattotargetapproachininflammatoryboweldiseaseasystematicreview
AT panaccioneremo outcomesandstrategiestosupportatreattotargetapproachininflammatoryboweldiseaseasystematicreview